News
10-19-2010, 12:00 AM
The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer.
More... (http://www.news-medical.net/news/20101019/NCCN-updates-Clinical-Practice-Guidelines-for-Breast-Cancer.aspx)
More... (http://www.news-medical.net/news/20101019/NCCN-updates-Clinical-Practice-Guidelines-for-Breast-Cancer.aspx)